Market Overview

Novartis -2.7% Premarket @$70.49, UBS Downgrade from Buy to Neutral

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for NVS

DateFirmActionFromTo
Jan 2017Credit SuisseDowngradesOutperformNeutral
Jan 2017JP MorganDowngradesOverweightNeutral
Nov 2016Argus ResearchUpgradesHoldBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: UBSNews Downgrades Price Target Legal Pre-Market Outlook Analyst Ratings Movers

 

Related Articles (NVS)